NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
5.73
Dollar change
-0.20
Percentage change
-3.37
%
IndexRUT P/E- EPS (ttm)-0.09 Insider Own3.51% Shs Outstand307.92M Perf Week0.35%
Market Cap1.76B Forward P/E22.18 EPS next Y0.26 Insider Trans-0.00% Shs Float297.12M Perf Month-7.73%
Enterprise Value1.96B PEG- EPS next Q-0.11 Inst Own99.78% Short Float7.03% Perf Quarter-32.03%
Income-29.37M P/S3.25 EPS this Y51.94% Inst Trans2.92% Short Ratio4.16 Perf Half Y-41.47%
Sales543.14M P/B9.12 EPS next Y398.57% ROA-3.89% Short Interest20.90M Perf YTD-39.17%
Book/sh0.63 P/C7.04 EPS next 5Y- ROE-18.12% 52W High12.65 -54.70% Perf Year-40.93%
Cash/sh0.81 P/FCF1095.93 EPS past 3/5Y41.55% 34.10% ROIC-4.67% 52W Low5.51 3.99% Perf 3Y-47.58%
Dividend Est.- EV/EBITDA34.94 Sales past 3/5Y20.03% 23.72% Gross Margin89.08% Volatility4.05% 3.43% Perf 5Y-63.17%
Dividend TTM- EV/Sales3.60 EPS Y/Y TTM80.86% Oper. Margin8.80% ATR (14)0.23 Perf 10Y-58.84%
Dividend Ex-Date- Quick Ratio2.47 Sales Y/Y TTM28.25% Profit Margin-5.41% RSI (14)40.71 Recom1.36
Dividend Gr. 3/5Y- - Current Ratio3.34 EPS Q/Q55.88% SMA20-3.51% Beta0.52 Target Price16.20
Payout- Debt/Eq2.29 Sales Q/Q13.45% SMA50-8.94% Rel Volume1.09 Prev Close5.93
Employees499 LT Debt/Eq2.25 EarningsMay 01 BMO SMA200-35.45% Avg Volume5.03M Price5.73
IPOMay 31, 2007 Option/ShortYes / Yes EPS/Sales Surpr.-29.15% -7.82% Trades Volume5,467,318 Change-3.37%
Date Action Analyst Rating Change Price Target Change
Dec-13-24Downgrade Morgan Stanley Overweight → Equal-Weight $17 → $12
Sep-06-24Initiated Jefferies Buy $18
May-30-24Initiated Wells Fargo Overweight $18
May-14-24Upgrade Guggenheim Neutral → Buy $13
Dec-19-23Upgrade Morgan Stanley Equal-Weight → Overweight $15 → $20
Sep-09-22Initiated Morgan Stanley Equal-Weight $14
Apr-13-22Resumed Goldman Neutral $11
Jan-14-22Upgrade SVB Leerink Mkt Perform → Outperform $12 → $16
Nov-15-21Upgrade Stifel Hold → Buy $12 → $16
Sep-30-21Upgrade JP Morgan Neutral → Overweight $16
Jun-25-25 07:00AM
Jun-24-25 12:45PM
Jun-03-25 07:45AM
07:00AM
May-30-25 07:00AM
08:51AM Loading…
May-13-25 08:51AM
May-07-25 07:00AM
May-02-25 01:18PM
May-01-25 04:24PM
10:44AM
09:48AM
08:15AM
07:17AM
07:00AM
Apr-30-25 07:12PM
10:01AM Loading…
Apr-29-25 10:01AM
Apr-24-25 10:01AM
Apr-23-25 12:57PM
09:25AM
Apr-21-25 07:00AM
Apr-17-25 08:21AM
Apr-15-25 08:17AM
Apr-11-25 01:18PM
08:21AM
Apr-09-25 01:44PM
10:58AM
Apr-08-25 10:06AM
Apr-07-25 01:22PM
Apr-02-25 01:38PM
Apr-01-25 03:00PM
10:50AM Loading…
10:50AM
06:55AM
Mar-28-25 12:00PM
Mar-21-25 11:30AM
10:10AM
Mar-17-25 03:37PM
Mar-12-25 07:29PM
Feb-27-25 07:00AM
Feb-23-25 01:30PM
Feb-20-25 09:30AM
02:05AM
02:03AM
Feb-19-25 08:30AM
07:00AM
Feb-17-25 09:16AM
Feb-12-25 10:00AM
Feb-10-25 07:00AM
Feb-03-25 07:00AM
Jan-20-25 02:58PM
Jan-17-25 11:19AM
Jan-12-25 04:00PM
09:35AM
Jan-02-25 07:00AM
Dec-13-24 02:10PM
09:50AM
Dec-06-24 11:31AM
Nov-07-24 09:50AM
02:09AM
12:26AM
Nov-06-24 08:30PM
08:25AM
07:22AM
07:00AM
Nov-04-24 09:55AM
Nov-01-24 07:00AM
Oct-30-24 10:01AM
Oct-28-24 07:00AM
Oct-21-24 09:50AM
Oct-18-24 12:20PM
09:55AM
09:55AM
06:41AM
Oct-17-24 11:07AM
07:00AM
Oct-09-24 05:35PM
Oct-07-24 05:02PM
Oct-04-24 07:00AM
Sep-24-24 11:50PM
Sep-03-24 07:46AM
07:05AM
07:00AM
Aug-30-24 07:00AM
Aug-21-24 11:24AM
Aug-09-24 10:31AM
Aug-08-24 09:00PM
08:25AM
07:22AM
07:00AM
Jul-30-24 07:00AM
Jun-26-24 09:47AM
Jun-05-24 07:00AM
Jun-04-24 07:00AM
May-24-24 08:30AM
May-14-24 07:15AM
May-10-24 04:03PM
01:10PM
11:33AM
10:46AM
May-09-24 10:30PM
11:56AM
Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Campbell Bradley LPresident and CEOFeb 19 '25Option Exercise9.034003,6121,151,057Feb 21 07:27 PM
Campbell Bradley LPresident and CEOFeb 19 '25Sale10.004004,0001,150,657Feb 21 07:27 PM
BRADLEY CAMPBELLDirectorFeb 19 '25Proposed Sale9.854003,940Feb 19 04:36 PM
Campbell Bradley LPresident and CEODec 02 '24Option Exercise8.617,50064,575894,154Dec 03 06:12 PM
Campbell Bradley LPresident and CEODec 02 '24Sale10.027,50075,124886,654Dec 03 06:12 PM
BRADLEY CAMPBELLDirectorDec 02 '24Proposed Sale9.987,50074,850Dec 02 04:43 PM
Campbell Bradley LPresident and CEONov 06 '24Option Exercise12.287,90197,024894,555Nov 07 05:49 PM
Campbell Bradley LPresident and CEONov 06 '24Sale12.507,90198,800886,654Nov 07 05:49 PM
BRADLEY CAMPBELLDirectorNov 06 '24Proposed Sale11.747,90192,758Nov 06 05:03 PM
Campbell Bradley LPresident and CEONov 01 '24Option Exercise8.617,50064,575894,154Nov 04 06:23 PM
Campbell Bradley LPresident and CEONov 01 '24Sale11.467,50085,960886,654Nov 04 06:23 PM
BRADLEY CAMPBELLDirectorNov 01 '24Proposed Sale11.427,50085,650Nov 01 04:49 PM
Campbell Bradley LPresident and CEOOct 01 '24Option Exercise8.617,50064,575894,154Oct 04 04:05 PM
Campbell Bradley LPresident and CEOOct 01 '24Sale10.607,50079,492886,654Oct 04 04:05 PM
BRADLEY CAMPBELLDirectorOct 01 '24Proposed Sale10.687,50080,100Oct 01 04:35 PM
Campbell Bradley LPresident and CEOSep 03 '24Option Exercise8.617,50064,575894,154Sep 05 05:01 PM
Campbell Bradley LPresident and CEOSep 03 '24Sale11.717,50087,798886,654Sep 05 05:01 PM
BRADLEY CAMPBELLDirectorSep 03 '24Proposed Sale11.617,50087,075Sep 03 04:19 PM
Campbell Bradley LPresident and CEOAug 01 '24Option Exercise8.617,50064,575894,154Aug 05 08:10 PM
Campbell Bradley LPresident and CEOAug 01 '24Sale10.347,50077,518886,654Aug 05 08:10 PM
BRADLEY CAMPBELLDirectorAug 01 '24Proposed Sale10.317,50077,325Aug 01 04:25 PM
Campbell Bradley LPresident and CEOJul 05 '24Option Exercise8.616,10052,521892,754Jul 09 05:01 PM
Campbell Bradley LPresident and CEOJul 05 '24Sale10.006,10061,029886,654Jul 09 05:01 PM